BostonGene Receives Frost & Sullivan's 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms
Recognition highlights BostonGene's leadership in improving drug development decisions, reducing risk and accelerating patient impact SAN ANTONIO, May 5, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that BostonGene has been...